Molecular structure of Nateglinide, CAS Number: 105816-04-4
Nateglinide (CAS 105816-04-4)
Alternate Names:
N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanine; D-Nateglinide; Fastic
Application:
Nateglinide is an amino-acid derivative that stimulates insulin secretion
CAS Number:
105816-04-4
Molecular Weight:
317.42
Molecular Formula:
C19H27NO3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Classified as a meglitinide, Nateglinide acts as a rapid-acting insulin secretagogue. By selectively and potently stimulating insulin secretion from the pancreas, Nateglinide effectively reduces blood glucose levels. Nateglinide achieves its effects by binding to the SUR1 subunit of the ATP-sensitive potassium channel, which is located on the surface of pancreatic β-cells. This binding event induces their depolarization and subsequent opening of voltage-gated calcium channels, enabling calcium ions to enter the cell. This calcium influx triggers the fusion of insulin-containing vesicles with the cell membrane, leading to insulin release.
Nateglinide (CAS 105816-04-4) References
- The mechanisms underlying the unique pharmacodynamics of nateglinide. | Hu, S., et al. 2003. Diabetologia. 46 Suppl 1: M37-43. PMID: 12652357
- Nateglinide (Starlix): update on a new antidiabetic agent. | Phillips, LS. and Dunning, BE. 2003. Int J Clin Pract. 57: 535-41. PMID: 12918894
- Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. | McLeod, JF. 2004. Clin Pharmacokinet. 43: 97-120. PMID: 14748619
- Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. | Scheen, AJ. 2007. Clin Pharmacokinet. 46: 93-108. PMID: 17253883
- A review of nateglinide in the management of patients with type 2 diabetes. | Tentolouris, N., et al. 2007. Vasc Health Risk Manag. 3: 797-807. PMID: 18200800
- Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. | Israel, MK., et al. 2008. Vasc Health Risk Manag. 4: 1167-78. PMID: 19337530
- Nateglinide controlled release tablet containing compressionable enteric coated granules. | Makino, C., et al. 2010. Chem Pharm Bull (Tokyo). 58: 1136-41. PMID: 20823590
- Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism. | Kitahara, Y., et al. 2011. Biol Pharm Bull. 34: 671-6. PMID: 21532155
- Nateglinide Exerts Neuroprotective Effects via Downregulation of HIF-1α/TIM-3 Inflammatory Pathway and Promotion of Caveolin-1 Expression in the Rat's Hippocampus Subjected to Focal Cerebral Ischemia/Reperfusion Injury. | Saad, MAE., et al. 2020. Inflammation. 43: 401-416. PMID: 31863220
- Co-processing of nateglinide with meglumine for enhanced dissolution rate: in vitro and in vivo evaluation. | Bazeed, AY., et al. 2020. Drug Dev Ind Pharm. 46: 1676-1683. PMID: 32892654
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. | Zhang, YS., et al. 2021. Front Endocrinol (Lausanne). 12: 735824. PMID: 34721294
- The Nitrated Form of Nateglinide Induces Apoptosis in Human Pancreatic Cancer Cells Through a Caspase-dependent Mechanism. | Nishi, K., et al. 2022. Anticancer Res. 42: 1333-1338. PMID: 35220224
- Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus. | Naushad, SM., et al. 2022. Pharmacol Rep. 74: 1083-1091. PMID: 35932448
- Characterization of binding by repaglinide and nateglinide with glycated human serum albumin using high-performance affinity microcolumns. | Ovbude, ST., et al. 2022. J Sep Sci. 45: 4176-4186. PMID: 36168862
- The effect of Nateglinide and Octreotide on follicular morphology and free radical scavenging system in letrazole-induced rat model of PCOS. | Kirici, P., et al. 2022. Eur Rev Med Pharmacol Sci. 26: 8893-8902. PMID: 36524509
Inhibitor of:
Amylase 2A, Amylase 2B, GIP, Glucagon Receptor, Oatp2, Olr808, PTP IA-2β, SLC22A29, SUR1, and UGT1A8.Activator of:
GLP1, IGRP, Insulin, PPAR gamma, SGLT-5, SUR-1, and SUR1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nateglinide, 10 mg | sc-394067 | 10 mg | $192.00 | |||
Nateglinide, 25 mg | sc-394067A | 25 mg | $265.00 |